Thus, the release of the bioactive cytokine from the ECM, e.g., during wound healing, inflammation, or cancer development and progression, mainly by matrix metalloproteinases (MMPs) or thrombospondin-1, rapidly increases TGF-β bioavailability and subsequently accelerated TGF-β signal transduction. The gene discussed is TGFB1; the disease is cancer.